Table 3 Main outcomes measures, for total calculation and subgroups
| Â | Studies (n) | Participants (n) | Rate in intervention (%) | I2 (%) | Participants (n) | Rate in control (%) | I2 (%) | Risk ratio | I2 (%) |
|---|---|---|---|---|---|---|---|---|---|
Oral treatment | 5 | 1584 | 0.2 (0.0–1.0) | 57 | 1187 | 2.5 (1.7–3.5) | 0 | 0.29 (0.15–0.57) | 0 |
10-day course | 3 | 308 | 0.0 (0.0–0.3) | 0 | 292 | 1.3 (0.3–2.9) | 0 | 0.28 (0.05–1.67) | 0 |
Single dose | 2 | 1276 | 0.8 (0.4–1.4) | 0 | 895 | 3.0 (2.0–4.2) | 0 | 0.29 (0.14–0.60) | 0 |
Topical treatment | 1 | 505 | 1.2 (0.4–2.3) | N/A | 490 | 1.6 (0.7–2.9) | N/A | 0.73 (0.25–2.08) | N/A |
Total | 6 | 2089 | 0.4 (0.1–1.1) | 55 | 1677 | 2.2 (1.6–3.0) | 5 | 0.38 (0.22–0.66) | 0 |